The Financial Post reports in its Thursday edition that trading in Home Capital Group (HCG) was dull on Wednesday. The Post's Barry Critchley writes that volume was lower than the previous few days, and the shares reversed the previous day's gains. There was one piece of interesting news: two of the 10 analysts who cover HCG revised their price targets. Laurentian Bank analyst Marc Charbin hiked his share target to $20 from $17 while Cormark analyst Jeff Fenwick lifted his target to $18 from $17.50. Mr. Charbin says in his previous modelling of HCG he had accounted for the cash and dilutive effect of the second Berkshire Hathaway tranche. Given the second tranche was rejected, removing its effects leads to a higher book value per share ($22.10 vs. $19.46) and higher earnings per share. "We continue to value HCG by applying a 0.9 times price-to-book value multiple, which results in a $20 target on our revised BVPS," he wrote, arguing the target price could be realized by the first quarter of 2018. Mr. Charbin is the outlier among the 10 analysts: two of them (Mr. Charbin and Dylan Steuart from Industrial Alliance) rate it a buy; seven a hold and one a sell. Price targets range from $13 to $20.